The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells

BACKGROUND: Chemotherapy resistance is the main cause of the marginal clinical benefit of platinum-based chemotherapy and tyrosine kinase inhibitors in advanced non-small-cell lung cancer (NSCLC). Thus, the identification of new therapeutic agents that can enhance the sensitivity of these drugs is o...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Keilani, Maha S, Alzoubi, Karem H, Jaradat, Saied A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186900/
https://www.ncbi.nlm.nih.gov/pubmed/30349406
http://dx.doi.org/10.2147/CPAA.S174074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186900/
https://www.ncbi.nlm.nih.gov/pubmed/30349406
http://dx.doi.org/10.2147/CPAA.S174074

Ejemplares similares